KFAS
APLS

Keating Financial Advisory Services’s Apellis Pharmaceuticals APLS Stock Holding History

Keating Financial Advisory Services’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11
Closed -$443 – 2617
2026
Q1 		$443 Buy
+11
New +$237 ﹤0.01% 2282

Other funds holding APLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Keating Financial Advisory Services's APLS Position: Q2 2026 in Review

Keating Financial Advisory Services sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 11 shares — an estimated $443 sold.

Keating Financial Advisory Services first reported a position in APLS in Q1 2026 and held it in 1 quarter. The position peaked at $443 in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • Keating Financial Advisory Services reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Keating Financial Advisory Services sold 11 Apellis Pharmaceuticals shares in Q2 2026, an estimated $443.
  • Keating Financial Advisory Services first reported a position in Apellis Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Keating Financial Advisory Services's Apellis Pharmaceuticals position peaked at $443 in Q1 2026.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.